New Senior Vice President Operations
Daniel Lund with many years’ experience in quality, production and supply chain management from the pharmaceutical industry, including AstraZeneca and Pfizer, has been recruited to a new role as Senior Vice President (SVP) Operations. At the same time, Jonas Östregård assumes responsibility for Marketing. Both Daniel and Jonas are members of the management team and report to the CEO.
“Daniel Lund has a broad and deep expertise in quality, logistics and supply chain management from the pharmaceutical industry. He has extensive experience in creating efficient processes and flows throughout the value chain from supplier to end customers. The combination of committed leadership, commercial focus and solid process know-how has led to a flying start. I am very happy to welcome Daniel to the management team in Bactiguard, where he will be a key person in our future development,” says Christian Kinch.
Daniel Lund is 43 years old and has held several senior positions in product development, quality, logistics and supply chain management at AstraZeneca, Medivir and Pfizer. He is a civil engineer from Luleå University of Technology and most recently comes from a position as Director Supply Chain at Pfizer in Strängnäs. He replaces Johan Rugfelt, who has taken on a new position as Senior Advisor to the management team.
Jonas Östregård, who was recruited from AstraZeneca to the role of Vice President Sales in August 2018, will at the same time assume responsibility for Marketing. In this capacity, he replaces marketing manager Nina Nilsson who will take up an external position.
Bactiguard's management now consists of the following executives:
Christian Kinch, CEO
Cecilia Edström, CFO
Daniel Lund, SVP Operations
Jonas Östregård, SVP Sales & Marketing
For further information, please contact:
Cecilia Edström, CFO, cell phone: +46 72 226 23 28
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com